Using PBPK Models to Predict Effects of Hepatic Impairment & DDI in Olanzapine/Samidorphan Combination Therapy
Olanzapine is an effective antipsychotic medication used to treat schizophrenia, a disease that affects about 1 in 300 people worldwide.1 However, side effects such as weight gain can cause patients to become less likely to take the medication as directed.2
The importance of PBPK modeling
PBPK modeling is becoming more widely accepted by regulatory agencies around the world. This cost-effective, powerful tool can provide the evidence needed to determine DDI risks without relying on clinical trials involving sensitive patient groups.